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We expanded second-line tuberculosis (TB) drug 
susceptibility testing for extensively drug-resistant Myco-
bacterium tuberculosis isolates from South Africa. Of 19 
patients with extensively drug-resistant TB identiﬁ  ed during 
February 2008–April 2009, 13 (68%) had isolates resistant 
to all 8 drugs tested. This resistance leaves no effective 
treatment with available drugs in South Africa.
E
xtensively drug-resistant tuberculosis (XDR TB) 
was  ﬁ   rst reported in 2005 and has been identiﬁ  ed 
worldwide (1,2). XDR TB is associated with poor treatment 
outcomes (3), especially among persons co-infected with 
HIV (4,5). XDR TB strains are created when multidrug-
resistant TB (MDR TB) is inadequately treated, which 
enables ampliﬁ  cation of second-line drug resistance (6,7). 
Inadequate treatment for XDR TB may result in additional 
resistance, severely limiting options for effective treatment.
Drug-susceptibility testing (DST) for ﬁ  rst-line  and 
second-line TB drugs is essential for developing effective 
MDR TB and XDR TB treatment regimens (8,9). However, 
DST requires laboratory facilities that are unavailable in 
most settings with high incidence of TB. In the last global 
report of drug resistance, only one third of countries 
conducted routine DST on suspected cases of TB; the 
remaining countries restricted testing to high-risk patients 
(2). Thus, most high-incidence settings use standardized 
MDR TB or XDR TB treatment regimens based on 
epidemiologic data from periodic drug-resistance surveys. 
Because the epidemiology of drug-resistant TB is changing 
rapidly (10), successful use of standardized regimens 
depends on accurate population-level drug-resistance data.
In 2005, a large HIV-associated XDR TB epidemic 
was detected in Tugela Ferry, South Africa (5). Continuous, 
routine drug resistance surveillance for all suspected TB 
cases has since been implemented in Tugela Ferry and >500 
XDR TB cases have been diagnosed; >90% of patients are 
coinfected with HIV. Most early XDR TB isolates from 
Tugela Ferry were resistant to 4 or 5 drugs (isoniazid, 
rifampin, oﬂ  oxacin, and kanamycin, plus ethambutol or 
streptomycin) (4). XDR TB isolates have become resistant 
to an increasing number of  drugs, such that by 2007, >90% 
were resistant to all 6 ﬁ  rst-line and second-line drugs tested 
(Figure 1) (4).
DST for other second-line drugs (in addition to 
oﬂ   oxacin and kanamycin) is not routinely performed 
in South Africa. However, the standardized XDR TB 
treatment regimen includes second-line drugs for which 
drug resistance data are lacking. Thus, we sought to further 
characterize second-line TB drug resistance among XDR 
TB isolates in Tugela Ferry by expanding DST to include 
capreomycin and ethionamide.
The Study
This study was conducted in Tugela Ferry, South 
Africa, where TB incidence is ≈1,100 cases/100,000 
population and >80% of TB case-patients are HIV infected. 
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Figure 1. Drug resistance among extensively drug-resistant 
tuberculosis isolates from Tugela Ferry, South Africa, 2005–2009: 
4-drug resistance = isoniazid (INH), rifampin (RIF), oﬂ  oxacin (OFL), 
and kanamycin (KM); 5-drug resistance = INH, RIF, OFL, KM, and 
ethambutol (EMB) or streptomycin (SM); 6-drug resistance = INH, 
RIF, OFL, KM, EMB, and SM. Column for 2008–2009 indicates 
study population.Increasing Drug Resistance in XDR TB
MDR TB and XDR TB incidence was 118 cases and 72 
cases/100,000 population, respectively, in 2007 (4). 
Ethical approval for this study was obtained from Albert 
Einstein College of Medicine, Yale University, University 
of KwaZulu-Natal, and the KwaZulu-Natal Department of 
Health.
We performed a prospective cross-sectional study 
actively identifying patients with suspected TB in medical 
and TB wards, the HIV clinic, and the outpatient department 
at the Tugela Ferry district hospital during February 2008–
April 2009. A person with suspected TB was deﬁ  ned as 
someone having a self-reported cough of any duration or 
>2 other signs or symptoms, including fever, night sweats, 
weight loss, or shortness of breath for any duration. Patients 
could be either newly manifesting TB symptoms or have 
been receiving TB treatment for >2 months but currently 
reporting active TB symptoms (i.e., treatment failures). 
One sputum specimen was obtained for culture and DST.
Sputum for this study was tested by microscopic 
analysis of auramine- and Ziehl-Nielsen–stained smears 
and Middlebrook 7H11 agar and Mycobacterial Growth 
Indicator Tube 960 broth culture. Identiﬁ  cation  of 
Mycobacterium tuberculosis was conﬁ   rmed by using 
niacin and nitrate reductase tests. DST of positive 
cultures was performed by using the 1% proportional 
method on Middlebrook 7H11 agar for isoniazid (critical 
concentrations: isoniazid 0.2 μg/mL, rifampin 1.0 μg/mL, 
ethambutol 7.5 μg/mL, streptomycin  2.0 μg/mL, oﬂ  oxacin 
2 μg/mL, kanamycin 5.0 μg/mL, capreomycin 10 μg/mL, 
and ethionamide 5.0 μg/mL). DST was repeated on all 
drug-resistant isolates to conﬁ  rm the observed resistance 
pattern.
Medical records were reviewed for demographic and 
clinical data. The proportion of patients with XDR TB and 
drug-susceptibility patterns were described by using simple 
frequencies. XDR TB treatment outcomes were reported as 
of November 2009; standard international deﬁ  nitions were 
used (11). 
Of 912 enrolled patients with suspected TB, 209 (23%) 
had culture-positive TB (Figure 2). Of these patients, 30 
(14%) had MDR TB, of which 19 (63% of those with MDR 
TB; 9% with culture-positive results) had XDR TB.
Among XDR TB isolates, all 19 (100%) were resistant 
to all 6 drugs routinely tested in KwaZulu-Natal Province 
(isoniazid, rifampin, ethambutol, streptomycin, oﬂ  oxacin, 
and kanamycin), which extended the trend seen in previous 
years toward increasing drug resistance (Figure 1). Of these 
isolates, 4 (21%) were also resistant to capreomycin, and 13 
(68%) were resistant to capreomycin and ethionamide (Table 
1). Thus, an 8-drug resistance pattern was the predominant 
DST type among XDR TB patients in this cohort.
Of 13 patients with 8-drug resistance XDR TB, 5 
(38%) were women (median age 33.5 years, range 24–51 
years) (Table 2). Although 5 (38%) had previously received 
(or currently showed failure to) ﬁ  rst-line TB treatment, 
none had ever received treatment with second-line drugs 
for MDR TB. Seven (54%) patients were identiﬁ  ed from 
the ambulatory HIV clinic. Twelve (92%) patients were 
HIV infected (median CD4 cell count 183.5 cells/mm3, 
range 22–670 cells/mm3); only 2 (17%) were receiving 
antiretroviral therapy at the time of TB screening.
Among 13 XDR TB patients with 8-drug resistance, 7 
(54%) died (median time to death 59 days, range 16–205 
days). Two patients were lost to follow-up, and 4 (31%) are 
still living and receiving XDR TB treatment (range 190–
502 days of follow-up). No trend in survival of patients 
with XDR TB was observed by drug-resistance pattern (6-
drug vs 7-drug vs. 8-drug).
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Figure 2. Determination of prevalence of tuberculosis (TB) and 
drug resistance among persons with suspected TB, Tugela Ferry, 
South Aﬁ  ca, 2008–2009. DST, drug susceptibility testing; MDR TB, 
multidrug-resistant TB; XDR TB, extensively drug-resistant TB.
Table 1. Drug susceptibility test results for 19 XDR TB patients, 
South Africa* 
Drug resistance pattern (antibiogram)  No. (%) patients 
INH, RIF, EMB, SM, OFL, KM  2 (11) 
INH, RIF, EMB, SM, OFL, KM, CAP  4 (21) 
INH, RIF, EMB, SM, OFL, KM, CAP, ETO  13 (68) 
Total 19 (100) 
*XDR TB, extensively drug-resistant tuberculosis; INH, isoniazid; RIF, 
rifampin; EMB, ethambutol; SM, streptomycin; OFL, ofloxacin; KM, 
kanamycin; CAP, capreomycin; ETO, ethionamide. Conclusions
Routine drug-resistance surveillance to ﬁ  rst-  and 
second-line drugs is conducted in Tugela Ferry, which 
has a high incidence of TB and HIV co-infection. In this 
study, we expanded second-line testing for 2 additional 
bactericidal drugs (capreomycin and ethionamide) for 
treatment of patients with XDR TB. Resistance to 8 ﬁ  rst-
line and second-line drugs is the predominant pattern 
for XDR TB in Tugela Ferry, thereby severely limiting 
effective therapeutic options with available medications. 
According to the standard XDR TB regimen used in 
this province, patients were receiving <3 active drugs 
(pyrazinamide,  p-aminosalicylic acid, and cycloserine), 
which increases the risk for treatment failure and further 
ampliﬁ  cation of drug resistance. These ﬁ  ndings underscore 
the need for routine surveillance for resistance to all ﬁ  rst-
line and second-line drugs used and for tailoring regimens 
accordingly to improve treatment success and reduce 
emergence of more drug-resistant XDR TB strains.
This study had 3 main limitations. First, the reliability 
of second-line DST is variable, and only recently have 
methods and critical concentrations been standardized 
(12). However, all drug-resistant isolates in this study had 
DST repeated to conﬁ  rm observed results. Second, DST 
for other ﬁ  rst-line drugs, such as pyrazinamide, and other 
second-line drugs was not conducted, although these drugs 
are often used for XDR TB treatment. Thus, the degree of 
drug resistance was likely to be only a minimum estimate. 
Third, although the proportion of XDR TB cases in this 
survey was high, the absolute number of XDR TB cases 
was low. This small sample size limits our ability to make 
conclusions about treatment outcomes for patients with 
increasing drug-resistant isolates. However, previous 
studies from our site have shown poorer survival rates with 
increasing drug resistance (4).
Expanded DST for second-line and third-line drugs 
is critical for XDR TB patient care. Given continued high 
and rapid number of deaths from XDR TB, better and more 
rapid methods for second-line DST are urgently needed 
to improve diagnosis and guide treatment. Although new 
drugs are being developed, efforts must target prevention 
of XDR TB and its transmission, earlier identiﬁ  cation of 
cases, support of treatment completion for TB and MDR 
TB, and greater use of antiretroviral therapy for patients 
who are co-infected with HIV.
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Table 2. Characteristics of 30 MDR TB and XDR TB patients, South Africa* 
Characteristic MDR TB  6- or 7-drug XDR TB  8-drug XDR TB 
Total  11 6 13
Female sex  8 (73)  4 (67)  5 (38) 
Age, y, median (range)  36 (26–52)  42.5 (36–64)  33.5 (24–51) 
Prior TB treatment 
 First-line  drugs†  5 (45)  5 (83)  5 (38) 
 Second-line  drugs‡  0 0 0
TB contact  2 (18)  2 (33)  1 (8) 
Enrollment site at HIV clinic  8 (73)  2 (33)  7 (54) 
HIV positive  10 (91)  5 (83)  12 (92) 
CD4 cell count, cells/mm
3, median (range)  155 (25–708)  117.5 (18–426)  183.5 (22–670) 
Receiving antiretroviral therapy (among HIV-positive patients)  7 (70)  2 (40)  2 (17) 
*Values are no. (%) unless otherwise indicated. MDR TB, multidrug-resistant tuberculosis; XDR TB, extensively drug-resistant TB. 6-drug resistance, 
resistance to isoniazid, rifampin, ethambutol, ofloxacin, kanamycin, and streptomycin; 7-drug resistance, resistance to isoniazid, rifampin, ethambutol, 
ofloxacin, kanamycin, streptomycin, and capreomycin; 8-drug resistance, resistance to isoniazid, rifampin, ethambutol, ofloxacin, kanamycin, 
streptomycin, capreomycin, and ethionamide. 
†First-line drugs used for treatment of persons with new TB cases or confirmed drug-susceptible TB include isoniazid, rifampin, ethambutol, and 
pyrazinamide. 
‡Second-line drugs used for treatment of persons with confirmed MDR TB include ofloxacin, kanaymycin, ethionamide, p-aminosalicylic acid, and 
cycloserine or terizidone. Increasing Drug Resistance in XDR TB
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